Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, has announced a 50:50 joint venture with Mind Medicine Australia $(MMA)$ to establish a psychedelic-assisted therapies clinic in Melbourne. The new entity, Mind Medicine Australia Clinics, aims to deliver an integrated suite of services, including clinical operations, governance, and medical oversight, to support a network of authorized prescribers across Australia. This collaboration is set to enhance treatment access for individuals with complex mental health conditions such as PTSD and treatment-resistant depression by reducing costs and increasing capacity. The clinic will also serve as a Centre of Excellence for clinician training, strengthening Incannex's position in the next-generation mental health treatment sector. MMA, renowned for its role in the regulatory rescheduling of psilocybin and MDMA, will provide essential resources and expertise to ensure the success of this initiative.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。